{"filing":{"accession_number":"0001437749-26-021442","cik":"0001668243","ticker":"URGN","company_name":"UroGen Pharma Ltd.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"urgn20260622_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926021442/urgn20260622_8k.htm"},"events":[{"id":13165,"run_id":11685,"accession_number":"0001437749-26-021442","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Shareholders approved six proposals at the Annual Meeting: election of seven directors, approval of Amended and Restated Articles of Association, amendments to the Compensation Policy and 2017 Equity Incentive Plan, an advisory vote on named executive officer compensation, and engagement of PricewaterhouseCoopers LLP as independent auditor. All proposals passed with substantial majorities.","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10232,"accession_number":"0001437749-26-021442","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports shareholder approval of an amendment and restatement of the Company's Articles of Association to align shareholder proposal eligibility with Israeli Companies Law requirements. While this is a governance matter involving shareholder voting and charter amendments, it is a routine administrative modification that would not materially affect a reasonable investor's assessment of the registrant's business, financial condition, or prospects. The amendment addresses procedural eligibility requirements rather than substantive rights or economic interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10233,"accession_number":"0001437749-26-021442","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of two compensation-related amendments: (i) an amendment to the Non-Employee Director and Officer Compensation Policy regarding directors' and officers' insurance, and (ii) an amendment to the 2017 Equity Incentive Plan increasing authorized shares by 1,000,000. Both amendments directly affect compensatory arrangements for directors and officers, fitting the exec_compensation category. The materiality is high given the equity plan expansion and policy modifications affecting executive and director compensation structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10234,"accession_number":"0001437749-26-021442","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from an Annual Meeting. The filing reports voting outcomes on six proposals: election of seven directors, approval of Amended and Restated Articles of Association, Compensation Policy Amendment, 2017 Equity Incentive Plan amendment, advisory vote on named executive officer compensation, and engagement of PricewaterhouseCoopers LLP as independent auditor. All proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10232,"accession_number":"0001437749-26-021442","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports shareholder approval of an amendment and restatement of the Company's Articles of Association to align shareholder proposal eligibility with Israeli Companies Law requirements. While this is a governance matter involving shareholder voting and charter amendments, it is a routine administrative modification that would not materially affect a reasonable investor's assessment of the registrant's business, financial condition, or prospects. The amendment addresses procedural eligibility requirements rather than substantive rights or economic interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-23"},{"id":10233,"accession_number":"0001437749-26-021442","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on shareholder approval of two compensation-related amendments: (i) an amendment to the Non-Employee Director and Officer Compensation Policy regarding directors' and officers' insurance, and (ii) an amendment to the 2017 Equity Incentive Plan increasing authorized shares by 1,000,000. Both amendments directly affect compensatory arrangements for directors and officers, fitting the exec_compensation category. The materiality is high given the equity plan expansion and policy modifications affecting executive and director compensation structures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-23"},{"id":10234,"accession_number":"0001437749-26-021442","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from an Annual Meeting. The filing reports voting outcomes on six proposals: election of seven directors, approval of Amended and Restated Articles of Association, Compensation Policy Amendment, 2017 Equity Incentive Plan amendment, advisory vote on named executive officer compensation, and engagement of PricewaterhouseCoopers LLP as independent auditor. All proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:15:41.500046+00:00","company_name":"UroGen Pharma Ltd.","ticker":"URGN","filing_date":"2026-06-23"}]}